AU
UK
CA
US
IND
NZ
Last update at 2026-06-18T13:30:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -0.65600M | -5.96000M | -8.51100M | -40.87000M | -26.50200M |
| Minority interest | - | - | - | - | - |
| Net income | 0.83M | -5.82400M | -8.44800M | -40.93500M | -26.51200M |
| Selling general administrative | 1.70M | - | 5.71M | 10.34M | 9.66M |
| Selling and marketing expenses | - | - | 0.21M | 0.24M | 0.43M |
| Gross profit | 1.93M | 0.92M | 0.03M | -1.44000M | -1.52000M |
| Reconciled depreciation | 0.17M | - | - | 1.44M | 1.52M |
| Ebit | -7.18200M | -5.84100M | -8.55700M | -41.13500M | -26.93400M |
| Ebitda | -7.01000M | -5.39100M | -7.76300M | -39.69500M | -25.41400M |
| Depreciation and amortization | 0.17M | 0.45M | 0.79M | 1.44M | 1.52M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -7.18200M | -6.25900M | -8.45700M | -40.85700M | -26.39100M |
| Other operating expenses | 7.20M | 6.45M | 8.56M | 20.26M | 26.91M |
| Interest expense | 0.06M | 0.12M | 0.08M | 0.20M | 0.26M |
| Tax provision | 0.00000M | - | - | 0.07M | 0.01000M |
| Interest income | 0.01M | - | - | 0.01M | 0.03M |
| Net interest income | -0.05200M | - | - | -0.18500M | -0.11600M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -1.48600M | -0.13600M | -0.19100M | 0.07M | 0.01000M |
| Total revenue | 0.02M | 0.19M | 0.10M | 0.00000M | 0.00000M |
| Total operating expenses | 9.11M | 7.18M | 8.49M | 20.26M | 26.91M |
| Cost of revenue | -1.91000M | -0.73300M | 0.07M | 1.44M | 1.52M |
| Total other income expense net | 6.53M | 0.30M | -0.05400M | -0.01300M | -0.11100M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 0.83M | - | - | -40.93500M | -26.51200M |
| Net income applicable to common shares | - | - | - | -40.93500M | -26.51200M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 4.30M | 9.93M | 16.28M | 19.72M | 79.94M |
| Intangible assets | 0.02M | 0.41M | 0.05M | 0.86M | 35.28M |
| Earning assets | - | - | - | - | - |
| Other current assets | 1.00M | 0.99M | 3.74M | 0.45M | 0.25M |
| Total liab | 1.86M | 26.05M | 9.98M | 15.40M | 36.30M |
| Total stockholder equity | 2.44M | -16.12000M | 6.30M | 4.32M | 43.64M |
| Deferred long term liab | - | - | - | 0.41M | 0.47M |
| Other current liab | 0.66M | 0.69M | 1.53M | 4.21M | 4.86M |
| Common stock | 9.22M | 8.22M | 32.95M | 78.58M | 78.58M |
| Capital stock | 9.22M | - | - | 78.58M | 78.58M |
| Retained earnings | -363.36600M | -364.19600M | -358.37200M | -349.94700M | -308.99700M |
| Other liab | - | - | - | 4.86M | 20.75M |
| Good will | 0.00000M | - | 0.34M | 0.00000M | 0.88M |
| Other assets | - | - | - | 4.13M | 6.71M |
| Cash | 1.71M | 4.20M | 7.00M | 12.45M | 30.02M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 1.82M | 2.85M | 2.93M | 10.43M | 13.83M |
| Current deferred revenue | 0.65M | 0.79M | 0.51M | 1.33M | 1.46M |
| Net debt | -1.70800M | 13.34M | -5.94600M | -12.19000M | -27.38600M |
| Short term debt | - | 0.14M | 0.16M | 0.14M | 0.90M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | - | 17.54M | 1.06M | 0.26M | 2.63M |
| Other stockholder equity | - | 0.00000M | 0.00000M | 6.32M | 6.32M |
| Property plant equipment | - | - | - | 0.31M | 3.25M |
| Total current assets | 3.50M | 6.51M | 11.12M | 14.82M | 34.29M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | - | 3.86M | 7.95M |
| Short term investments | - | - | - | 0.00000M | 0.00000M |
| Net receivables | 0.79M | 0.91M | 0.38M | 1.26M | 2.34M |
| Long term debt | - | - | - | - | - |
| Inventory | 0.00000M | 0.42M | -0.07700M | - | - |
| Accounts payable | 0.51M | 1.23M | 1.24M | 4.75M | 6.61M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 356.59M | 339.86M | 331.73M | 269.36M | 267.73M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.03M | 0.10M | 2.94M | 3.72M | 6.24M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 0.80M | 3.41M | 5.16M | 4.89M | 45.65M |
| Capital lease obligations | 0.00000M | - | - | 0.26M | 2.63M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | - | - | 7.20M | -0.12600M |
| Change to liabilities | - | - | - | -4.32100M | 2.96M |
| Total cashflows from investing activities | 3.01M | - | - | 7.20M | -0.12600M |
| Net borrowings | - | - | - | -0.89600M | -1.13600M |
| Total cash from financing activities | 1.39M | 2.98M | 9.36M | 3.24M | 39.52M |
| Change to operating activities | - | - | - | -4.01500M | 1.41M |
| Net income | 0.83M | -5.82400M | -8.44800M | -40.93500M | -26.51200M |
| Change in cash | -2.49200M | - | -5.44100M | -17.57300M | 12.78M |
| Begin period cash flow | 4.20M | 7.00M | 12.45M | 30.02M | 17.23M |
| End period cash flow | 1.71M | 4.20M | 7.00M | 12.45M | 30.02M |
| Total cash from operating activities | -6.90000M | -5.68000M | -15.20200M | -28.01000M | -26.64300M |
| Issuance of capital stock | 0.96M | - | - | - | 36.57M |
| Depreciation | 0.17M | 0.45M | 0.79M | 1.44M | 1.52M |
| Other cashflows from investing activities | - | - | 1.34M | 0.23M | 0.27M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | 0.07M | -0.41700M | - | -0.30600M | - |
| Change to account receivables | - | - | -1.20500M | 0.31M | -1.55900M |
| Sale purchase of stock | - | - | - | -0.12400M | - |
| Other cashflows from financing activities | 0.43M | 2.98M | 9.50M | 4.14M | 40.66M |
| Change to netincome | - | - | - | 15.50M | -3.05600M |
| Capital expenditures | 0.00000M | 0.12M | 0.90M | 0.12M | 0.39M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -1.47200M | -0.17700M | -1.20500M | -4.01500M | 1.41M |
| Stock based compensation | 0.12M | - | 0.94M | 1.62M | 2.17M |
| Other non cash items | -6.43000M | -0.12900M | -7.27800M | 13.88M | -4.69700M |
| Free cash flow | -6.90000M | -5.68000M | -16.10100M | -28.13300M | -27.03600M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CLYYF Celyad Oncology SA |
- -% | 0.25 | 17.50 | - | 790.54 | 5.46 | 609.28 | 12.00 |
| NVO Novo Nordisk A/S |
2.69 6.23% | 45.88 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
1.60 3.69% | 45.00 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
15.16 3.36% | 466.79 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
2.56 0.42% | 612.50 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Celyad Oncology SA, a biotechnology company, focuses on the research and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through Immuno-Oncology and Cardiology segments. The company develops short hairpin ribonucleic acid (shRNA) non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the T-cell receptor (TCR) without the need for gene editing; NKG2D-based CAR T-cells and multi-specific CAR T-cell platform; and B7-H6 targeting CAR T-cells. It also engages in the development of CYAD-01, a CAR T-cell product candidate based on the natural killer group 2D (NKG2D); CYAD-02, an autologous NKG2D-based CAR T-cell candidate used to target the NKG2D ligands (NKG2DL) MICA/B to prevent cell fratricide and improve cell persistence; and CYAD-211, an allogeneic B-cell maturation antigen (BCMA)-targeting CAR T-cell candidate. In addition, the company offers C-Cathez, an intra-myocardial injection catheter. It has a license agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; research and development collaboration, and license agreements with Hr for the use of shRNA to downregulate such targets in immune cells and the combination of shRNAs with a chimeric antigen receptor in immune cells; and a license agreement with Mesoblast to develop and commercialize C-Cathez. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
Axis Business Park, Mont-Saint-Guibert, Belgium, 1435
| Name | Title | Year Born |
|---|---|---|
| Mr. Michel E. J. Lussier BME, M.B.A., M.S., MBA, MS BME | Co-Founder, CFO, Interim CEO & Director | 1956 |
| Mr. David Georges | VP of Fin. & Admin. | NA |
| Sara Zelkovic | Communications & Investor Relations Director | NA |
| Mr. Philippe Nobels | Chief HR Officer & VP of HR | 1966 |
| Dr. Charles Q. Morris M.D., MBChB, MRCP (UK), Ph.D. | Chief Medical Officer | 1965 |
| Ms. An Phan | Head of Legal | NA |
| Mr. Hannes Iserentant | Head of Intellectual Property | NA |
| Dr. Frédéric Lehmann | VP of Clinical Devel. & Medical Affairs | 1964 |
| Mr. Michel E. J. Lussier BME, M.B.A., M.S., MS BME | Co-Founder & Executive Director | 1956 |
| Mr. Matthew R. Kane | Chief Executive Officer | 1977 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...